Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Melanoma 22Neoplasms 6Carcinoma, Hepatocellular 5Stomach Neoplasms 4Recurrence 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Advanced Cancer 4Uveal Melanoma 3Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Liver Neoplasms 3Colonic Neoplasms 3Rectal Neoplasms 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasm Metastasis 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Hodgkin Disease 2Hematologic Neoplasms 2Glioma 2Glioblastoma 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Basal Cell 2Brain Neoplasms 2

Interventions

Sorafenib 68Bevacizumab 44Oxaliplatin 25Doxorubicin 22Gemcitabine 21Fluorouracil 21Radiosurgery 20Nivolumab 19durvalumab 18Radiofrequency Ablation 18pembrolizumab 17lenvatinib 17Cisplatin 17Capecitabine 17atezolizumab 14Leucovorin 14Hepatectomy 14Radiotherapy 12tremelimumab 10Irinotecan 10Drug Therapy 10Cyclophosphamide 10Carboplatin 10Blood Specimen Collection 10Ipilimumab 9regorafenib 8Liver Transplantation 8Everolimus 8Cryosurgery 8Chemotherapy, Adjuvant 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Liver Neoplasms × relatlimab × Clear all
NCT05337137 2026-01-12

RELATIVITY-106

Bristol-Myers Squibb

Phase 1/2 Completed
83 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04567615 2026-01-08

A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

Bristol-Myers Squibb

Phase 2 Completed
266 enrolled 28 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04658147 2025-12-18

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Active not recruiting
31 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡